SCHEMBL6473271

SCHEMBL6473271

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2ccc(CCNS(C)(=O)=O)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 4/20 0.49
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA5A P35218 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ACACB O00763 2/20 0.37
ACACA Q13085 1/20 0.37
TP53 P04637 1/20 0.36
KDM4E B2RXH2 2/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
F10 P00742 1/20 0.35
PRSS1 P07477 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473902 0.94 GRIA4 (0.41) GRIA4ADRB2ADRB1ADRB3CA12
SCHEMBL6480391 0.88 TP53 (0.40) GRIA4SMN1; SMN2ACACBTP53KDM4E
SCHEMBL6473739 0.87 CA1 (0.44) GRIA4ADRB2ADRB1ADRB3CA12
SCHEMBL6482324 0.87 GRIA4 (0.46) GRIA4CA12CA2ACACBACACA
SCHEMBL6482281 0.86 ACACB (0.50) ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL6480376 0.85 MAOB (0.45) GRIA4ADRB2ADRB1ADRB3CA12
SCHEMBL6481831 0.85 GAA (0.40) ADRB2ADRB1ADRB3CA12CA1
SCHEMBL6473264 0.85 GRIA4 (0.68) GRIA4ADRB2ADRB1ADRB3CA12
SCHEMBL6475845 0.84 GRIA4 (0.41) GRIA4CA1CA2ALDH1A1SMN1; SMN2
SCHEMBL6766134 0.83 MEN1 (0.42) GRIA4ADRB2ADRB1ADRB3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885ADRB2 1991/4885ADRB1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.